CCR is proud to participate in the Cancer Moonshot, one of NCI’s key initiatives. The Cancer Moonshot seeks to accelerate cancer research to make more therapies available to more patients, while also improving our ability to prevent cancer and detect it at an early stage. Moonshot projects are based on a 2016 Blue Ribbon Panel Report, which describes 10 transformative research recommendations for achieving the Cancer Moonshot's ambitious goal of making a decade's worth of progress in cancer prevention, diagnosis, and treatment in just 5 years. Below are CCR’s funded projects:
CCR Moonshot Project | Blue Ribbon Panel Recommendation |
---|---|
Goal: Build a national network to study selected rare pediatric and adult tumors and develop a network of clinical trials. NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors. NCI-CONNECT aims to advance the understanding of rare adult central nervous system (CNS) cancers by establishing and fostering patient-advocacy-provider partnerships and networks to improve approaches to care and treatment. MyPART: Moonshot Pediatric, Adolescent, and Adult Rare Tumors Network. MyPART focuses on research across a range of pediatric, adolescent, and young adult rare solid tumors. | Establish a network for direct patient involvement |
Goal: Build a trans-NIH cell-based therapy center for development and dissemination of cutting-edge immunotherapy approaches. | Create a translational science network devoted exclusively to immunotherapy. |
Goal: Develop a library of 1 million pre-fractionated natural product pools to be made available for screening to the extramural community and to provide natural products screening expertise and infrastructure. | Develop new cancer technologies |
Goal: Catalyze intramural and extramural T Cell Receptor (TCR) gene therapy research. | Create a translational science network devoted exclusively to immunotherapy |
Goal: Development and psychometric testing of a pediatric chronic symptom scale (PCSS). | Minimize cancer treatment’s debilitating side effects |
Goal: To determine the clinical impact of PET imaging of prostate-specific membrane antigen (PSMA) on patients with high-risk prostate cancer who have negative conventional imaging (CT and bone scan). | Develop new cancer technologies |